Ultragenyx Pharmaceutical Inc.
RARE Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 28.1%, EPS grew 23.1% and free cash flow grew 12.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow RARE
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
425.25 | 680.00 | 413.00 | 292.00 |
Receivables |
112.54 | 158.00 | 121.00 | 200.00 | |
Inventory |
52.20 | 52.00 | 55.00 | 59.00 | |
Total current assets |
643.21 | 951.00 | 657.00 | 606.00 | |
Property, Plant, Equpment (Net) |
249.96 | 244.00 | 239.00 | 235.00 | |
Long-Term Investments |
22.07 | 57.00 | 121.00 | 144.00 | |
Goodwill and Intangible Assets (Total) |
217.35 | 220.00 | 218.00 | 216.00 | |
Long-term assets (Other) |
57.86 | 60.00 | 61.00 | 63.00 | |
Total non-current assets |
547.24 | 581.00 | 639.00 | 658.00 | |
Total Assets |
1,190.45 | 1,532.00 | 1,296.00 | 1,264.00 | |
Accounts Payable |
40.57 | 31.00 | 42.00 | 39.00 | |
Accrued Expenses |
220.53 | 265.00 | 194.00 | 221.00 | |
Other current liabilities |
66.78 | 88.00 | 89.00 | 91.00 | |
Total current liabilities |
340.02 | 384.00 | 325.00 | 351.00 | |
Long Term Tax Liability (Deferred) |
30.06 | 30.00 | 30.00 | 30.00 | |
Minority Interests |
7.00 | 7.00 | 7.00 | 7.00 | |
Non-current Liabilities (Other) |
782.52 | 1,191.00 | 1,170.00 | 1,167.00 | |
Total non-current liabilities |
841.26 | 1,228.00 | 1,207.00 | 1,204.00 | |
Total liabilities |
1,181.29 | 1,612.00 | 1,532.00 | 1,555.00 | |
Additional Paid In Capital |
4,411.53 | 4,451.00 | 4,481.00 | 4,518.00 | |
Common Stock (Net) |
0.10 | — | — | — | |
Retained Earnings |
(4,403.29) | (4,532.00) | (4,717.00) | (4,809.00) | |
Treasury Stock |
7.99 | 8.00 | 10.00 | 10.00 | |
Common Equity (Total) |
9.16 | (80.00) | (236.00) | (291.00) | |
Shareholders Equity (Total) |
9.16 | (80.00) | (236.00) | (291.00) | |
Shareholders Equity and Liabilities (Total) |
1,190.45 | 1,532.00 | 1,296.00 | 1,264.00 | |
Shares (Common) |
96.44 | 96.60 | 98.30 | 98.60 | |
Shareholders Equity (Tangible) |
(208.19) | (300.00) | (454.00) | (507.00) | |
Net Debt |
(425.25) | (680.00) | (413.00) | (292.00) |